- Home
- INCY vs H Comparison
INCY vs H Comparison
Compare INCY & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- H
- Stock Information
- Founded
- INCY 1991
- H 1957
- Country
- INCY United States
- H United States
- Employees
- INCY N/A
- H N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- H Hotels/Resorts
- Sector
- INCY Health Care
- H Consumer Discretionary
- Exchange
- INCY Nasdaq
- H Nasdaq
- Market Cap
- INCY 13.4B
- H 12.8B
- IPO Year
- INCY 1993
- H 2009
- Fundamental
- Price
- INCY $67.11
- H $132.92
- Analyst Decision
- INCY Hold
- H Buy
- Analyst Count
- INCY 20
- H 17
- Target Price
- INCY $71.94
- H $149.41
- AVG Volume (30 Days)
- INCY 1.9M
- H 1.1M
- Earning Date
- INCY 07-29-2025
- H 05-01-2025
- Dividend Yield
- INCY N/A
- H 0.45%
- EPS Growth
- INCY N/A
- H 23.10
- EPS
- INCY 0.10
- H 7.89
- Revenue
- INCY $4,413,226,000.00
- H $3,216,000,000.00
- Revenue This Year
- INCY $13.29
- H $112.35
- Revenue Next Year
- INCY $10.47
- H $5.56
- P/E Ratio
- INCY $691.99
- H $16.92
- Revenue Growth
- INCY 17.13
- H N/A
- 52 Week Low
- INCY $53.56
- H $102.43
- 52 Week High
- INCY $83.95
- H $168.20
- Technical
- Relative Strength Index (RSI)
- INCY 66.68
- H 60.09
- Support Level
- INCY $63.51
- H $127.54
- Resistance Level
- INCY $66.26
- H $133.12
- Average True Range (ATR)
- INCY 1.92
- H 3.06
- MACD
- INCY 0.30
- H -0.29
- Stochastic Oscillator
- INCY 67.34
- H 55.79
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.